Residency · Residency · Respirology

Hemoptysis - Evaluation and Management

Definition and Classification

Definitions

Hemoptysis is defined as the expectoration of blood originating from the lower respiratory tract, specifically from structures below the glottis. An essential first step in evaluation is differentiating true hemoptysis from two mimicking conditions: hematemesis, in which blood originates from the gastrointestinal tract, and pseudohemoptysis, in which blood originates from the upper airway or oral cavity and is expectorated by the patient, creating the impression of a pulmonary source. Several features help distinguish these entities. Hemoptysis typically produces bright red, frothy blood that is alkaline in pH and mixed with sputum. Hematemesis, by contrast, tends to produce dark red or brown blood, may contain food particles, is acidic in pH, and is associated with nausea or vomiting. Pseudohemoptysis from oral or nasopharyngeal sources is often accompanied by visible bleeding from the gums, nose, or posterior pharynx on examination. Clarifying the source is critical, as the differential diagnosis, diagnostic approach, and management differ fundamentally.

Severity Classification

Hemoptysis is classified by severity into non-massive and massive categories, though it is important to recognize that no universally accepted volumetric threshold defines the boundary between the two. Non-massive (mild to moderate) hemoptysis, which accounts for the majority of presentations, is generally defined as less than 100 to 200 mL per 24 hours, with the patient maintaining hemodynamic stability and an uncompromised airway. Massive hemoptysis, though less common, carries extraordinary mortality and has been variably defined in the literature: commonly cited thresholds include more than 200 to 600 mL per 24 hours (with considerable variation among sources), a bleeding rate exceeding 100 mL per hour, or, most pragmatically, any volume of hemoptysis that causes hemodynamic instability, respiratory compromise, or airway obstruction. The mortality of untreated massive hemoptysis ranges from 50% to 80%, and the mechanism of death is characteristically asphyxiation from airway flooding rather than hemorrhagic shock. This critical distinction informs the immediate management priority: protecting the airway and maintaining gas exchange takes absolute precedence over volume resuscitation.

Anatomy of Pulmonary Blood Supply

Understanding the dual blood supply of the lungs is essential for comprehending the pathophysiology and management of hemoptysis. The bronchial arteries, which operate at systemic arterial pressures and carry only 1% to 2% of cardiac output, are the source of approximately 90% of hemoptysis cases. These arteries arise from the descending aorta, typically at the T5-T6 vertebral level, though anatomic variants are common. In the setting of chronic inflammation, such as bronchiectasis, tuberculosis, or cystic fibrosis, the bronchial arteries undergo marked hypertrophy and neovascularization, becoming fragile, tortuous vessels that are prone to rupture. The pulmonary arteries, which operate at low pressures, are the source of approximately 5% of hemoptysis cases, occurring in specific pathologies such as Rasmussen aneurysm (erosion of a pulmonary artery branch by a tuberculous cavity), pulmonary artery pseudoaneurysm (from Swan-Ganz catheter injury), and pulmonary arteriovenous malformations. Non-bronchial systemic collateral vessels, including branches from the intercostal, internal mammary, and subclavian arteries, develop in the setting of chronic lung disease and may contribute to hemoptysis, particularly when prior bronchial artery embolization has been performed.

Etiology

Common Causes by Frequency

The etiology of hemoptysis spans a broad differential diagnosis organized by pathophysiologic category. Infection is the most common cause of hemoptysis overall, with acute bronchitis being the single most frequent etiology of mild hemoptysis. Other infectious causes include pneumonia, tuberculosis (both active disease and post-tuberculous sequelae including bronchiectasis and Rasmussen aneurysm), lung abscess, and fungal infections, most notably aspergilloma (mycetoma). Bronchiectasis, whether from cystic fibrosis or other etiologies, is a major cause of recurrent and sometimes massive hemoptysis due to chronic airway inflammation with bronchial artery hypertrophy and neovascularization. Malignancy accounts for a significant proportion of hemoptysis, with lung cancer being the predominant neoplasm; centrally located tumors, classically squamous cell carcinoma, are most likely to produce hemoptysis through direct erosion into bronchial vessels, while carcinoid tumors and pulmonary metastases are less common malignant causes.

Cardiovascular causes include pulmonary embolism with pulmonary infarction, mitral stenosis (now rarely seen in developed countries due to the decline of rheumatic heart disease), congestive heart failure, and pulmonary arteriovenous malformations. Autoimmune and vasculitic diseases represent an important category, including granulomatosis with polyangiitis (GPA, formerly Wegener's), microscopic polyangiitis, Goodpasture syndrome (anti-glomerular basement membrane disease), Behcet disease, and systemic lupus erythematosus. These conditions may cause diffuse alveolar hemorrhage (DAH), a distinct syndrome characterized by hemorrhage from the pulmonary capillaries into the alveolar spaces, associated with bilateral ground glass opacities on imaging and often an elevated DLCO (exceeding 140% of predicted, as free hemoglobin within the alveoli absorbs carbon monoxide).

Iatrogenic causes include anticoagulation therapy (which typically unmasks an underlying structural lesion rather than serving as the primary cause), lung biopsy, bronchoscopy, Swan-Ganz catheter injury, and transthoracic needle aspiration. Additional causes include aspergilloma (fungus ball forming in a pre-existing pulmonary cavity), Dieulafoy lesion of the bronchial mucosa, pulmonary endometriosis causing catamenial hemoptysis, foreign body aspiration, and thoracic trauma. Importantly, in 15% to 30% of cases, a thorough workup fails to identify a definitive cause, and the hemoptysis is classified as cryptogenic.

<image>A comprehensive etiologic classification diagram for hemoptysis. Display a central bronchial tree illustration with branching arrows pointing to six etiologic categories arranged around it: (1) Infectious - showing TB cavity with Rasmussen aneurysm, aspergilloma in cavity, necrotizing pneumonia; (2) Neoplastic - central lung mass with endobronchial component; (3) Bronchiectasis - dilated airways with hypertrophied bronchial arteries; (4) Vascular - PE with pulmonary infarction, AVM (showing aberrant vessel), mitral stenosis with pulmonary venous hypertension; (5) Autoimmune/DAH - diffuse alveolar hemorrhage showing bilateral ground glass pattern on CT, with microscopic view of capillaritis; (6) Iatrogenic - Swan-Ganz catheter tip in PA branch. Include approximate frequency percentages for each category. Label the bronchial arterial supply (from aorta at T5-T6) as the source in 90% of cases.</image>

Diagnostic Evaluation

Initial Assessment

The initial assessment of hemoptysis follows the ABCs of emergency management: airway, breathing, and circulation. The severity of bleeding must be assessed immediately, as it determines the urgency and trajectory of the subsequent workup. Vital signs, including blood pressure, heart rate, respiratory rate, and oxygen saturation, establish the presence or absence of hemodynamic and respiratory compromise. The history should attempt to quantify the volume of blood expectorated, recognizing that patients tend to overestimate; useful reference points include a tablespoon (approximately 15 mL) and a cup (approximately 240 mL). The temporal pattern (acute versus chronic, intermittent versus continuous), associated symptoms (fever and weight loss suggesting infection or malignancy, pleuritic pain suggesting pulmonary embolism, dyspnea), and medication review (with specific attention to anticoagulants and antiplatelet agents) provide diagnostic direction. Risk factor assessment includes smoking history (malignancy risk), tuberculosis exposure or endemic area travel, known bronchiectasis or cystic fibrosis, autoimmune disease, and prior episodes of hemoptysis.

Laboratory Studies

Laboratory evaluation serves both to assess the severity of blood loss and to guide the etiologic workup. A complete blood count identifies anemia suggesting significant or ongoing blood loss, while leukocytosis may point to an infectious etiology. Coagulation studies (PT/INR, aPTT, platelet count) identify coagulopathy that may be contributing to bleeding or that requires correction before procedural intervention. A basic metabolic panel and type and screen are obtained in anticipation of potential resuscitation needs. Sputum studies, including Gram stain, acid-fast bacilli smear and culture, and cytology (when malignancy is suspected), provide valuable diagnostic information. Urinalysis should be performed in all patients, as hematuria in the context of hemoptysis raises the critical possibility of a pulmonary-renal syndrome, such as granulomatosis with polyangiitis, microscopic polyangiitis, or Goodpasture syndrome. When diffuse alveolar hemorrhage is suspected, an autoimmune panel should be sent, including ANCA (c-ANCA/PR3 for GPA, p-ANCA/MPO for microscopic polyangiitis), anti-GBM antibodies, ANA, and complement levels. BNP may be obtained if a cardiac cause is suspected.

Imaging

Chest radiography is the first-line imaging study and can identify the laterality of bleeding (based on infiltrate location), masses, cavitary lesions, and other structural abnormalities. However, localization by chest radiograph alone is imprecise, with the infiltrate correlating with the bleeding side in only 60% to 70% of cases, and bilateral opacities may be present from aspirated blood. CT of the chest with intravenous contrast (CT angiography) is superior to plain radiography and has become the imaging study of choice for hemoptysis evaluation. CT identifies the cause in 60% to 77% of cases, localizes the bleeding site, delineates the bronchial artery anatomy for embolization planning, and detects masses, bronchiectasis, arteriovenous malformations, and pulmonary embolism. The current recommendation is to perform CT before bronchoscopy in most cases, as CT identifies peripheral lesions not accessible to the bronchoscope, guides bronchoscopic examination, and provides a roadmap for angiographic intervention. The exception is massive hemoptysis, in which emergent bronchoscopy for airway localization and control takes immediate priority.

Bronchoscopy

Flexible bronchoscopy is the first-line endoscopic tool for evaluating non-massive hemoptysis. It can localize bleeding to the lobar or segmental level in 70% to 90% of cases when performed during active bleeding, allows direct visual assessment of endobronchial lesions, and permits bronchoalveolar lavage for cytology, cultures, and assessment of hemosiderin-laden macrophages (diagnostic of DAH). Rigid bronchoscopy is preferred for massive hemoptysis because its larger working channel allows superior suctioning capacity, the ability to tamponade bleeding (via balloon catheter or gauze packing), and maintenance of ventilation through the rigid scope, all while maintaining airway control. Rigid bronchoscopy requires general anesthesia and an experienced operator. Regarding timing, early bronchoscopy performed within 24 to 48 hours of active hemoptysis significantly improves the rate of bleeding localization; in massive hemoptysis, emergent bronchoscopy is performed simultaneously with resuscitation for localization and temporization while preparations are made for definitive treatment.

Management

Non-Massive Hemoptysis

The management of non-massive hemoptysis focuses on identifying and treating the underlying cause. Antibiotics are administered for infectious etiologies, antituberculous therapy is initiated when indicated, and the decision to continue or hold anticoagulation is made based on individualized risk-benefit assessment, recognizing that anticoagulation may be resumed once bleeding is controlled if the indication is strong. General supportive measures include bed rest, positioning the patient with the bleeding lung dependent (if the side of bleeding has been identified) to protect the non-bleeding lung from blood aspiration, and cough suppression with codeine or dextromethorphan, though the latter is controversial as suppressing cough may increase the risk of blood retention and aspiration. Outpatient workup is acceptable for hemodynamically stable patients with small-volume hemoptysis, provided appropriate follow-up with imaging and potentially bronchoscopy can be arranged in a timely fashion.

Massive Hemoptysis - Emergency Management

Massive hemoptysis demands immediate, coordinated, multidisciplinary intervention. Airway protection is the first priority: a large-bore endotracheal tube (8.0 mm internal diameter or larger) should be placed to facilitate suctioning, and the patient should be positioned in the lateral decubitus position with the bleeding side down to use gravity to protect the non-bleeding lung from aspiration of blood. If the bleeding side is known, selective intubation of the non-bleeding mainstem bronchus may be performed: the right mainstem can be intubated by advancing a standard endotracheal tube, while left mainstem intubation requires a specialized tube or bronchoscopic guidance due to the more acute angulation of the left main bronchus. Large-bore intravenous access, crossmatching of blood products, and correction of coagulopathy with fresh frozen plasma, platelets, vitamin K, and tranexamic acid should proceed simultaneously.

Tranexamic acid has emerged as an important adjunct in hemoptysis management. Administered intravenously at 1 g every 8 hours or via nebulization at 500 mg in 5 mL of saline, tranexamic acid is an antifibrinolytic agent that stabilizes clot formation at the bleeding site. Systematic reviews suggest that it reduces bleeding duration and volume, though definitive data from large randomized controlled trials are still pending. Rigid bronchoscopy in the setting of massive hemoptysis provides airway control, bleeding localization, and temporization measures including cold saline lavage, topical epinephrine instillation, and balloon tamponade using a Fogarty catheter wedged in the bleeding segmental bronchus.

Bronchial Artery Embolization (BAE)

Bronchial artery embolization is the first-line definitive treatment for massive hemoptysis when the expertise and facilities are available. The procedure involves angiographic identification of the bleeding bronchial or non-bronchial systemic arteries followed by selective catheterization and embolization with embolic agents including polyvinyl alcohol particles, gelatin sponge, coils, or microspheres. The immediate success rate of bronchial artery embolization is 85% to 95%, making it a highly effective intervention. However, recurrence occurs in 10% to 30% of cases within 1 to 2 years, often requiring repeat embolization or consideration of surgical intervention.

The most feared complication of bronchial artery embolization is spinal cord ischemia, which can occur when the anterior spinal artery shares a common origin with the bronchial artery being embolized. The anterior spinal artery arises from the bronchial circulation in approximately 5% of patients, and its identification on angiography before embolization is absolutely critical. If the anterior spinal artery is found to originate from the target bronchial artery, embolization of that vessel must be avoided or performed with extreme caution using microcatheters positioned distal to the spinal artery takeoff. Other complications include bronchial necrosis (rare), chest pain, and transient dysphagia from esophageal branch embolization.

Surgical Management

Surgical intervention for hemoptysis is reserved for specific scenarios: failure of bronchial artery embolization, recurrent massive hemoptysis despite BAE, and localized disease amenable to definitive resection such as aspergilloma, carcinoid tumor, or single-lobe bronchiectasis. Emergency surgery in the setting of active massive hemoptysis carries a prohibitively high mortality rate of 20% to 40%, whereas elective surgery performed after hemodynamic stabilization and optimization has a much lower mortality of 1% to 5%. Lobectomy is the most commonly performed procedure, while pneumonectomy is a last-resort option carrying the highest perioperative mortality and long-term morbidity.

<image>An emergency management algorithm for massive hemoptysis. Start with massive hemoptysis (>200 mL/24h or respiratory/hemodynamic compromise). Immediate actions (parallel): secure airway (large ETT, consider double-lumen or selective intubation), position bleeding side down, IV access and resuscitate, correct coagulopathy (FFP, platelets, TXA), call interventional radiology and thoracic surgery. Next step: bronchoscopy (rigid preferred if available) for localization and temporization (cold saline, epinephrine, balloon tamponade). Decision node: bleeding localized and bronchial artery anatomy identified -> bronchial artery embolization (first-line definitive therapy, 85-95% success). If BAE fails or unavailable: surgical intervention (lobectomy, mortality 20-40% emergent). Post-stabilization: investigate underlying cause (TB, malignancy, bronchiectasis, AVM) and treat. Show critical safety note about anterior spinal artery identification before BAE.</image>

Special Scenarios

Aspergilloma (Mycetoma)

Aspergilloma, or mycetoma, is a fungus ball that develops within a pre-existing pulmonary cavity, most commonly arising from prior tuberculosis, sarcoidosis, or bullous emphysema. Hemoptysis is the most common clinical presentation and can be massive, driven by the hypertrophied bronchial arteries that develop around the cavity wall in response to chronic inflammation. The classic imaging finding is the "air crescent sign," in which a mobile intracavitary mass is surrounded by a crescentic rim of air; characteristically, the mass changes position with patient repositioning, confirming its mobile nature within the cavity. Management depends on the clinical presentation: for acute massive hemoptysis, bronchial artery embolization provides immediate hemostasis; for recurrent or life-threatening hemoptysis in patients with acceptable operative risk, surgical resection by lobectomy offers the most definitive treatment. Systemic antifungal therapy with itraconazole or voriconazole has limited efficacy for aspergilloma, as the fungus ball exists within a cavity with minimal blood supply, limiting drug delivery to the site of disease.

Diffuse Alveolar Hemorrhage (DAH)

Diffuse alveolar hemorrhage is a medical emergency characterized by bleeding from the pulmonary capillary bed into the alveolar spaces, typically caused by capillaritis from autoimmune or vasculitic conditions. The classic clinical triad consists of hemoptysis, bilateral alveolar infiltrates on imaging, and a dropping hemoglobin, though hemoptysis may be absent in up to 30% of cases despite active alveolar bleeding, making a high index of suspicion essential. Bronchoalveolar lavage is diagnostic: sequential aliquots demonstrate progressively bloodier returns, and cytologic analysis reveals hemosiderin-laden macrophages comprising more than 20% of total cells. An elevated DLCO exceeding 140% of predicted is a striking and distinctive finding, resulting from free hemoglobin within the alveoli absorbing carbon monoxide during the diffusion capacity maneuver.

Urgent autoimmune serologies should be sent, including ANCA (c-ANCA/PR3 and p-ANCA/MPO), anti-GBM antibodies, ANA, and complement levels, as results guide definitive therapy. Treatment is initiated empirically while awaiting results: pulse-dose methylprednisolone at 500 to 1000 mg intravenously daily for 3 days is administered for all suspected immune-mediated DAH. Cyclophosphamide is added for ANCA-associated vasculitis, and plasma exchange is the treatment of choice for anti-GBM disease (Goodpasture syndrome), in which the pathogenic antibody must be rapidly cleared from the circulation.

Pulmonary Arteriovenous Malformation (AVM)

Pulmonary arteriovenous malformations are abnormal direct connections between pulmonary arteries and pulmonary veins that bypass the capillary bed. The most common association is hereditary hemorrhagic telangiectasia (HHT, also known as Osler-Weber-Rendu syndrome), an autosomal dominant disorder in which 30% to 40% of affected individuals have pulmonary AVMs. Beyond hemoptysis, pulmonary AVMs create right-to-left shunts causing hypoxemia and paradoxical embolism, which can result in stroke and brain abscess as venous emboli bypass the pulmonary capillary filter. Screening for pulmonary AVMs is performed with contrast echocardiography (bubble study), which is more sensitive than chest CT for detecting small shunts. Treatment consists of transcatheter embolization for AVMs with a feeding artery diameter of 2 mm or greater, which eliminates the shunt and reduces the risk of paradoxical embolism and hemorrhagic complications.

Key Clinical Pearls

• The primary cause of death in massive hemoptysis is asphyxiation from airway flooding, NOT hemorrhagic shock; protecting the airway and maintaining gas exchange is the immediate priority
• Position the patient with the bleeding lung DOWN to protect the non-bleeding lung from blood aspiration; this is the opposite of what may seem intuitive
• Bronchial artery embolization is the first-line definitive treatment for massive hemoptysis with an 85-95% immediate success rate; always identify the anterior spinal artery on angiography to prevent catastrophic spinal cord ischemia
• CT chest should generally be performed before bronchoscopy in non-massive hemoptysis (identifies peripheral lesions and guides subsequent management); in massive hemoptysis, emergent bronchoscopy for airway control takes precedence
• An elevated DLCO (> 140% predicted) with bilateral ground glass opacities and dropping hemoglobin is virtually diagnostic of diffuse alveolar hemorrhage; hemoptysis may be absent in 30% of DAH cases

References

1. Davidson K, Shojaee S. Managing Massive Hemoptysis. Chest. 2020;157(1):77-88.
2. Sakr L, Dutau H. Massive hemoptysis: an update on the role of bronchoscopy in diagnosis and management. Respiration. 2010;80(1):38-58.
3. Defined Rasmussen V, Defined Defined, et al. Bronchial artery embolization for hemoptysis: a systematic review and meta-analysis. Cardiovasc Intervent Radiol. 2018;41(8):1126-1137.
4. Defined Defined, et al. Defined Defined. Am J Respir Crit Care Med. 2020;Defined.
5. Lara AR, Schwarz MI. Diffuse alveolar hemorrhage. Chest. 2010;137(5):1164-1171.

Read this lecture as Markdown